{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:12:52Z","timestamp":1774289572043,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40268-021-00378-9","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T09:02:43Z","timestamp":1644656563000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-7096","authenticated-orcid":false,"given":"Paul","family":"Hutson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis","family":"Guieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Claude","family":"Deharo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Brignole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassondra","family":"Vander Ark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed H.","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"issue":"5","key":"378_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2017.03.002","volume":"70","author":"WK Shen","year":"2017","unstructured":"Shen WK, et al. 2017 ACC\/AHA\/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017;70(5):620\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.03.002.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"378_CR2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1540-8167.2006.00595.x","volume":"17","author":"KS Ganzeboom","year":"2006","unstructured":"Ganzeboom KS, et al. Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35\u201360 years. J Cardiovasc Electrophysiol. 2006;17(11):1172\u20136. https:\/\/doi.org\/10.1111\/j.1540-8167.2006.00595.x.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"16","key":"378_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/eurheartj\/ehl147","volume":"27","author":"A Serletis","year":"2006","unstructured":"Serletis A, et al. Vasovagal syncope in medical students and their first-degree relatives. Eur Heart J. 2006;27(16):1965\u201370. https:\/\/doi.org\/10.1093\/eurheartj\/ehl147.","journal-title":"Eur Heart J"},{"issue":"12","key":"378_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1540-8167.2010.01848.x","volume":"21","author":"GL Sumner","year":"2010","unstructured":"Sumner GL, et al. Recent history of vasovagal syncope in a young, referral-based population is a stronger predictor of recurrent syncope than lifetime syncope burden. J Cardiovasc Electrophysiol. 2010;21(12):1375\u201380. https:\/\/doi.org\/10.1111\/j.1540-8167.2010.01848.x.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"378_CR5","unstructured":"Common Terminology Criteria for Adverse Events. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 4 Sept 2019."},{"issue":"3","key":"378_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45(3):925\u201337.","journal-title":"Biometrics"},{"issue":"1","key":"378_CR7","first-page":"108","volume":"92","author":"K Chaiyasit","year":"2009","unstructured":"Chaiyasit K, Khovidhunkit W, Wittayalertpanya S. Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai. 2009;92(1):108\u201313.","journal-title":"J Med Assoc Thai"},{"issue":"6653","key":"378_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/39807","volume":"389","author":"MJ Caterina","year":"1997","unstructured":"Caterina MJ, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816\u201324. https:\/\/doi.org\/10.1038\/39807.","journal-title":"Nature"},{"issue":"7","key":"378_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nchembio.1835","volume":"11","author":"F Yang","year":"2015","unstructured":"Yang F, et al. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nat Chem Biol. 2015;11(7):518\u201324. https:\/\/doi.org\/10.1038\/nchembio.1835.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"378_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40261-015-0311-9","volume":"35","author":"CK Gelotte","year":"2015","unstructured":"Gelotte CK, Zimmerman BA. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Clin Drug Investig. 2015;35(9):547\u201358. https:\/\/doi.org\/10.1007\/s40261-015-0311-9.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"378_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/bf00607955","volume":"30","author":"A Martinsson","year":"1986","unstructured":"Martinsson A, Beveg\u00e5rd S, Hjemdahl P. Analysis of phenylephrine in plasma: initial data about the concentration-effect relationship. Eur J Clin Pharmacol. 1986;30(4):427\u201331. https:\/\/doi.org\/10.1007\/bf00607955.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"378_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.2042-7158.2011.01326.x","volume":"63","author":"V Perera","year":"2011","unstructured":"Perera V, et al. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol. 2011;63(9):1161\u20138. https:\/\/doi.org\/10.1111\/j.2042-7158.2011.01326.x.","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"378_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/sj.ejcn.1600899","volume":"53","author":"ML Nurminen","year":"1999","unstructured":"Nurminen ML, et al. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr. 1999;53(11):831\u20139. https:\/\/doi.org\/10.1038\/sj.ejcn.1600899.","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"378_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3945\/ajcn.111.018267","volume":"95","author":"G Renda","year":"2012","unstructured":"Renda G, et al. Genetic determinants of blood pressure responses to caffeine drinking. Am J Clin Nutr. 2012;95(1):241\u20138. https:\/\/doi.org\/10.3945\/ajcn.111.018267.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"378_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2011-301411","volume":"98","author":"JC Deharo","year":"2012","unstructured":"Deharo JC, et al. Adenosine plasma level and A2A adenosine receptor expression: correlation with laboratory tests in patients with neurally mediated syncope. Heart. 2012;98(11):855\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2011-301411.","journal-title":"Heart"},{"key":"378_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15103","author":"KA Jacobson","year":"2020","unstructured":"Jacobson KA, et al. Adenosine A(2A) receptor antagonists: from caffeine to selective non-xanthines. Br J Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bph.15103 (Epub 18 May 2020).","journal-title":"Br J Pharmacol"},{"issue":"4","key":"378_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0002-9343(99)80315-5","volume":"98","author":"H Calkins","year":"1995","unstructured":"Calkins H, et al. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med. 1995;98(4):365\u201373. https:\/\/doi.org\/10.1016\/s0002-9343(99)80315-5.","journal-title":"Am J Med"},{"issue":"2","key":"378_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/hdi.12138","volume":"18","author":"JJ Sands","year":"2014","unstructured":"Sands JJ, et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int. 2014;18(2):415\u201322. https:\/\/doi.org\/10.1111\/hdi.12138.","journal-title":"Hemodial Int"},{"issue":"2","key":"378_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000168287","volume":"11","author":"O Stojceva-Taneva","year":"1991","unstructured":"Stojceva-Taneva O, et al. Autonomic nervous system dysfunction and volume nonresponsive hypotension in hemodialysis patients. Am J Nephrol. 1991;11(2):123\u20136. https:\/\/doi.org\/10.1159\/000168287.","journal-title":"Am J Nephrol"},{"issue":"12","key":"378_CR20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1681\/asn.V4121987","volume":"4","author":"T Shinzato","year":"1994","unstructured":"Shinzato T, et al. Role of adenosine in dialysis-induced hypotension. J Am Soc Nephrol. 1994;4(12):1987\u201394. https:\/\/doi.org\/10.1681\/asn.V4121987.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"378_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/0003-4819-123-1-199507010-00005","volume":"123","author":"K Yokokawa","year":"1995","unstructured":"Yokokawa K, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med. 1995;123(1):35\u20137. https:\/\/doi.org\/10.7326\/0003-4819-123-1-199507010-00005.","journal-title":"Ann Intern Med"},{"issue":"8","key":"378_CR22","first-page":"1421","volume":"10","author":"U Friess","year":"1995","unstructured":"Friess U, et al. Failure of arginine-vasopressin and other pressor hormones to increase in severe recurrent dialysis hypotension. Nephrol Dial Transplant. 1995;10(8):1421\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"378_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10286-007-1001-3","volume":"18","author":"PA Low","year":"2008","unstructured":"Low PA. Prevalence of orthostatic hypotension. Clin Auton Res. 2008;18(Suppl 1):8\u201313. https:\/\/doi.org\/10.1007\/s10286-007-1001-3.","journal-title":"Clin Auton Res"},{"issue":"6","key":"378_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMcp074189","volume":"358","author":"R Freeman","year":"2008","unstructured":"Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615\u201324. https:\/\/doi.org\/10.1056\/NEJMcp074189.","journal-title":"N Engl J Med"},{"issue":"14","key":"378_CR25","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/archinte.1994.00420140086011","volume":"154","author":"D Robertson","year":"1994","unstructured":"Robertson D, Robertson RM. Causes of chronic orthostatic hypotension. Arch Intern Med. 1994;154(14):1620\u20134.","journal-title":"Arch Intern Med"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00378-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00378-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T09:29:00Z","timestamp":1646040540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00378-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00378-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"20 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Multiple discretionary funds were used to support this study (MHH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Paul Hutson and Cassondra Vander Ark declare that they have no conflicts of interest. Regis Guieu, Jean-Claude Deharo, Pierre Michelet, Michele Brignole, and Mohamed H. Hamdan have a pending patent application entitled \u2018Sublingual Formulation for Hypotension and Syncope\u2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the University of Wisconsin Madison Human Subjects Committee (2018-1545), and performed under US IND 140732.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided signed informed consent before participating in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to pending patent applications but are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data. All authors either drafted the work or revised it critically for important intellectual content and approved the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}